Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jun 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how using electronic Patient Reported Outcomes (ePROs) can help doctors make better treatment decisions for patients with certain autoimmune diseases, including gout, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. The goal is to see if providing doctors with regular updates from patients about their health will lead to more frequent adjustments in their treatments. The researchers believe that when doctors have better insights into their patients' conditions, they can tailor therapies more effectively to meet individual needs.

To participate in this study, you must be at least 18 years old and have been diagnosed with one of the autoimmune diseases mentioned. You'll also need to have access to the internet and be comfortable using it, as you'll be providing feedback through online forms. If you join the trial, you can expect to share your health information regularly, which will help your doctor understand how well your treatment is working and if any changes are needed. It's important to know that the study will last for two years, and there are certain criteria that would exclude you from participation, like having a severe cognitive impairment or a life expectancy of less than one year.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or women of at least 18 years of age
• * Diagnosed with (at least) one of the following autoimmune diseases:
• • Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria,
• • Gout according to the 2015 EULAR/ACR classification criteria,
• • Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria
• • Sjogren's Syndrome according to the 2016 EULAR/ACR classification criteria
• • According to local regulations, patient has expressed his/her non-opposition (for France) or has provided written informed consent (for Switzerland and Germany) to participate in the study
• • Patient has access to the internet, a functioning email address and a mobile phone number
• • Patient physically and mentally able to use a computer tool connected to the Internet
• • Only in Switzerland \& Germany : patient is covered by a health insurance plan
• Exclusion Criteria:
• • Any neurodegenerative disease that alters cognitive faculties
• • Refractory cancer
• • Patients who do not have access to the Internet and/or do not master its use in the context of this protocol
• • Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders...) Subject who is compulsorily detained for psychiatric treatment
• • Patient who cannot be followed for 2 years by the investigating physician
• • Patient over the age of legal majority who is protected, or deprived of liberty by judicial or administrative decision (vulnerable subject)
• • Patient with an estimated life expectancy shorter than 1 year